SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Psychopharmacology
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Web of Science (8)
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Odagaki, Y.
Right arrow Articles by Yamauchi, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Odagaki, Y.
Right arrow Articles by Yamauchi, T.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*TRAZODONE HYDROCHLORIDE
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Trazodone and its active metabolite m-chlorophenylpiperazine as partial agonists at 5-HT1A receptors assessed by [35S]GTP{gamma}S binding

Yuji Odagaki

Ryoichi Toyoshima

Toshio Yamauchi

Department of Psychiatry, Saitama Medical School, Moroyama-machi, Iruma-gun, Saitama, Japan

Trazodone is an effective antidepressant drug with a broad therapeutic spectrum, including anxiolytic efficacy. Although trazodone is usually referred to as a serotonin (5-HT) reuptake inhibitor, this pharmacological effect appears to be too weak to fully account for its clinical effectiveness. The present study aimed to elucidate the agonist properties of trazodone and its active metabolite, m-chlorophenylpiperazine (m-CPP), at 5-HT1A receptors by means of the guanosine-5'-O-(3-[35S]thio)-triphosphate ([35S]GTP{gamma}S) binding assay. In membranes prepared from Chinese hamster ovary cells expressing human 5-HT1A receptors (CHO/h5-HT1A), trazodone behaved as an almost full agonist and m-CPP was also a highly efficacious partial agonist at 5-HT1A receptors. The intrinsic activities of both compounds were higher than those of tandospirone and buspirone, which are clinically effective anxiolytics with well-known 5-HT1A partial agonist properties. These effects were replicated in the 5-HT1A receptor-mediated [35S]GTP{gamma}S binding assay in native rat brain membranes (at least in hippocampal membranes), although the intrinsic activities of the compounds were low and differently ranked compared to those in CHO/h5-HT1A cell membranes. When considering the implications of 5-HT1A receptors in anxiety and/or depression, as well as the clinical effectiveness of azapirone anxiolytics with partial 5-HT1A receptor agonist properties such as buspirone, it is possible that the agonist effects on 5-HT1A receptors of trazodone and its active metabolite m-CPP presented in this study contribute, at least in part, to the clinical efficacy of the atypical antidepressant trazodone.

Key Words: buspirone • m-chlorophenylpiperazine (m-CPP) • 5-HT1A receptor • partial agonist • tandospirone • trazodone

Journal of Psychopharmacology, Vol. 19, No. 3, 235-241 (2005)
DOI: 10.1177/0269881105051526


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




Advertisement